ArticleAntimicrobial agents and chemotherapy2004
Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 76 citations in OpenAlex.
- Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections.Pharmaceutics · 2022Review
- Article
- Review of Contemporary Self-Assembled Systems for the Controlled Delivery of Therapeutics in Medicine.Nanomaterials (Basel, Switzerland) · 2021Review
- Nasal Gel Loaded with Amphotericin Nanotransferosomes as Antifungal Treatment for Fungal Sinusitis.Pharmaceutics · 2020Article
- Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs.Antimicrobial agents and chemotherapy · 2020Article
- Actinomycete-Derived Polyketides as a Source of Antibiotics and Lead Structures for the Development of New Antimicrobial Drugs.Antibiotics (Basel, Switzerland) · 2019Review
- The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?Pharmaceutics · 2019Article
- Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.Nanomedicine (London, England) · 2019Review
- RETRACTED: Preparation and Characterization of Spherical Amorphous Solid Dispersion with Amphotericin B.Pharmaceutics · 2018Article
- RNA-Seq Profile Reveals Th-1 and Th-17-Type of Immune Responses in Mice Infected Systemically with Aspergillus fumigatus.Mycopathologia · 2018Article
- Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications.Nanotechnology reviews · 2018Article
- The Smart Drug Delivery System and Its Clinical Potential.Theranostics · 2016Review
- Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis.Antimicrobial agents and chemotherapy · 2013Article
- Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections.Antimicrobial agents and chemotherapy · 2010Article
- NAC is associated with additional alleviation of lung injury induced by invasive pulmonary aspergillosis in a neutropenic model.Acta pharmacologica Sinica · 2009Article
- Review
- Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lys.Antimicrobial agents and chemotherapy · 2008Article
- Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.Antimicrobial agents and chemotherapy · 2008Article
- Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.Antimicrobial agents and chemotherapy · 2007Article
- Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.Antimicrobial agents and chemotherapy · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared various amphotericin B formulations (no treatment or 0.8 mg of Fungizone [conventional deoxycholate amphotericin B] per kg of body weight, or 0.8, 4, or 8 mg of Amphocil, AmBisome, or Abelcet per kg of body weight) for treatment of systemic murine aspergillosis. In two studies, all formulations prolonged survival, with the results for AmBisome nearly equivalent to those for Fungizone; Amphocil and Abelcet were less effective or equivalent depending on the severity of infection. No survivors were cured in both kidneys and brain, but each formulation showed efficacy, especially in the kidneys. Although higher doses could be given, no lipid-based formulation showed consistent superiority over Fungizone or over each other.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.